In this study based on a ‘’narrow/isolated’’ Finnish cohort, 21 low penetrance susceptibility loci were identified, of which 10 are novel. The intronic variant rs2074187 in SP6 was associated not only with overall susceptibility to PrCa (OR 1.66) but also with a higher odds ratio for aggressive PrCa (OR 1.89) and lower odds for non-aggressive PrCa (OR 1.43). Furthermore, the new intergenic variant rs79012498 at 8q24 conferred risk for aggressive PrCa. These are important as they are associated with significant prostate cancer. Such variants may be useful in the stratification of patients for population based screening.
The biological functional relation between the transcription factor SP6 and prostate cancer is plausible based on the existing literature, yet has to be investigated further. Likewise, the putative interaction with HOXB13 and CIP2A. Importantly, the population-stratified approach can lead to the revelation of yet unidentified PrCa susceptibility loci.
Written by: Jack A. Schalken, PhD, is a Professor of Experimental Urology and Director of Urological Research at Radboud University Medical Center in Nijmegen, The Netherlands
Read the Full-Text Article: Novel Prostate Cancer Susceptibility Gene SP6 Predisposes Patients to Aggressive Disease